Mair Therapeutics

Mair Therapeutics is an early-stage immuno-oncology biotechnology company focused on modulating the tumor microenvironment by targeting myeloid cell signaling. A spin-out from the Francis Crick Institute in London, the company leverages pioneering research into the Myeloid-Associated Immunoglobulin-like Receptor (MAIR) family, particularly CD300a, to reverse immune suppression in cancer. Their primary therapeutic approach involves developing monoclonal antibodies that inhibit these myeloid checkpoints, thereby enhancing the body's natural anti-tumor T-cell responses. Mair Therapeutics is currently advancing its pipeline through pre-clinical development to address the unmet needs of patients with resistant solid tumors. The company combines deep expertise in dendritic cell biology and innate immunology to create next-generation checkpoint inhibitors.